- Home
- CHRS vs TCRX Comparison
CHRS vs TCRX Comparison
Compare CHRS & TCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHRS
- TCRX
- Stock Information
- Founded
- CHRS 2010
- TCRX 2018
- Country
- CHRS United States
- TCRX United States
- Employees
- CHRS N/A
- TCRX N/A
- Industry
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- TCRX Biotechnology: Pharmaceutical Preparations
- Sector
- CHRS Health Care
- TCRX Health Care
- Exchange
- CHRS Nasdaq
- TCRX Nasdaq
- Market Cap
- CHRS 84.2M
- TCRX 82.1M
- IPO Year
- CHRS 2014
- TCRX 2021
- Fundamental
- Price
- CHRS $0.76
- TCRX $1.43
- Analyst Decision
- CHRS Buy
- TCRX Strong Buy
- Analyst Count
- CHRS 3
- TCRX 6
- Target Price
- CHRS $4.68
- TCRX $9.50
- AVG Volume (30 Days)
- CHRS 1.3M
- TCRX 649.6K
- Earning Date
- CHRS 08-07-2025
- TCRX 08-11-2025
- Dividend Yield
- CHRS N/A
- TCRX N/A
- EPS Growth
- CHRS N/A
- TCRX N/A
- EPS
- CHRS N/A
- TCRX N/A
- Revenue
- CHRS $272,251,000.00
- TCRX $4,421,000.00
- Revenue This Year
- CHRS N/A
- TCRX $159.20
- Revenue Next Year
- CHRS $106.56
- TCRX N/A
- P/E Ratio
- CHRS N/A
- TCRX N/A
- Revenue Growth
- CHRS 19.87
- TCRX N/A
- 52 Week Low
- CHRS $0.66
- TCRX $1.02
- 52 Week High
- CHRS $2.43
- TCRX $7.89
- Technical
- Relative Strength Index (RSI)
- CHRS 46.35
- TCRX 45.45
- Support Level
- CHRS $0.72
- TCRX $1.39
- Resistance Level
- CHRS $0.77
- TCRX $1.73
- Average True Range (ATR)
- CHRS 0.04
- TCRX 0.14
- MACD
- CHRS 0.00
- TCRX -0.02
- Stochastic Oscillator
- CHRS 38.69
- TCRX 10.03
About CHRS Coherus BioSciences Inc.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.
About TCRX TScan Therapeutics Inc.
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.